UTILIZZO DEL MEDROSSI PROGESTERONE ACETATO IN PAZIENTI NEOPLASTICI IN FASE AVANZATA

Translated title of the contribution: Use of medroxy progesterone acetate in advanced cancer patients

G. Acampora, A. Cuomo, M. Del Giudice, G. Russo, T. Sarubbi, P. L. Viscidi

Research output: Contribution to journalArticle

Abstract

The authors report their experiences about the use of medroxy progesterone acetate (MPA) in high doses in the palliative therapy of patients suffering from advanced cancer. The research was carried out on 120 patients no more capable to respond to any active therapy and only undergoing symptomatic treatment. The patients were treated for 12 weeks with MPA (1000 mg/die) and were weekly assessed for pain, cenaesthesia and, essentially, for quality of life. On the whole, the results emphasized a reduction of the painful syndrome, if present, an improvement of the psychological state and particularly of appetite, also by reason of the consequent reduced intake of analgesic and adjuvant drugs.

Original languageItalian
Pages (from-to)75-78
Number of pages4
JournalGiornale Italiano di Oncologia
Volume14
Issue number2
Publication statusPublished - 1994

Fingerprint

Progesterone
Acetates
Neoplasms
Appetite
Palliative Care
Analgesics
Quality of Life
Psychology
Pain
Therapeutics
Research

ASJC Scopus subject areas

  • Cancer Research

Cite this

Acampora, G., Cuomo, A., Del Giudice, M., Russo, G., Sarubbi, T., & Viscidi, P. L. (1994). UTILIZZO DEL MEDROSSI PROGESTERONE ACETATO IN PAZIENTI NEOPLASTICI IN FASE AVANZATA. Giornale Italiano di Oncologia, 14(2), 75-78.

UTILIZZO DEL MEDROSSI PROGESTERONE ACETATO IN PAZIENTI NEOPLASTICI IN FASE AVANZATA. / Acampora, G.; Cuomo, A.; Del Giudice, M.; Russo, G.; Sarubbi, T.; Viscidi, P. L.

In: Giornale Italiano di Oncologia, Vol. 14, No. 2, 1994, p. 75-78.

Research output: Contribution to journalArticle

Acampora, G, Cuomo, A, Del Giudice, M, Russo, G, Sarubbi, T & Viscidi, PL 1994, 'UTILIZZO DEL MEDROSSI PROGESTERONE ACETATO IN PAZIENTI NEOPLASTICI IN FASE AVANZATA', Giornale Italiano di Oncologia, vol. 14, no. 2, pp. 75-78.
Acampora, G. ; Cuomo, A. ; Del Giudice, M. ; Russo, G. ; Sarubbi, T. ; Viscidi, P. L. / UTILIZZO DEL MEDROSSI PROGESTERONE ACETATO IN PAZIENTI NEOPLASTICI IN FASE AVANZATA. In: Giornale Italiano di Oncologia. 1994 ; Vol. 14, No. 2. pp. 75-78.
@article{2418b185a997474dba0138bd2a19a7b6,
title = "UTILIZZO DEL MEDROSSI PROGESTERONE ACETATO IN PAZIENTI NEOPLASTICI IN FASE AVANZATA",
abstract = "The authors report their experiences about the use of medroxy progesterone acetate (MPA) in high doses in the palliative therapy of patients suffering from advanced cancer. The research was carried out on 120 patients no more capable to respond to any active therapy and only undergoing symptomatic treatment. The patients were treated for 12 weeks with MPA (1000 mg/die) and were weekly assessed for pain, cenaesthesia and, essentially, for quality of life. On the whole, the results emphasized a reduction of the painful syndrome, if present, an improvement of the psychological state and particularly of appetite, also by reason of the consequent reduced intake of analgesic and adjuvant drugs.",
keywords = "MPA, quality of life",
author = "G. Acampora and A. Cuomo and {Del Giudice}, M. and G. Russo and T. Sarubbi and Viscidi, {P. L.}",
year = "1994",
language = "Italian",
volume = "14",
pages = "75--78",
journal = "Giornale Italiano di Oncologia",
issn = "0392-128X",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "2",

}

TY - JOUR

T1 - UTILIZZO DEL MEDROSSI PROGESTERONE ACETATO IN PAZIENTI NEOPLASTICI IN FASE AVANZATA

AU - Acampora, G.

AU - Cuomo, A.

AU - Del Giudice, M.

AU - Russo, G.

AU - Sarubbi, T.

AU - Viscidi, P. L.

PY - 1994

Y1 - 1994

N2 - The authors report their experiences about the use of medroxy progesterone acetate (MPA) in high doses in the palliative therapy of patients suffering from advanced cancer. The research was carried out on 120 patients no more capable to respond to any active therapy and only undergoing symptomatic treatment. The patients were treated for 12 weeks with MPA (1000 mg/die) and were weekly assessed for pain, cenaesthesia and, essentially, for quality of life. On the whole, the results emphasized a reduction of the painful syndrome, if present, an improvement of the psychological state and particularly of appetite, also by reason of the consequent reduced intake of analgesic and adjuvant drugs.

AB - The authors report their experiences about the use of medroxy progesterone acetate (MPA) in high doses in the palliative therapy of patients suffering from advanced cancer. The research was carried out on 120 patients no more capable to respond to any active therapy and only undergoing symptomatic treatment. The patients were treated for 12 weeks with MPA (1000 mg/die) and were weekly assessed for pain, cenaesthesia and, essentially, for quality of life. On the whole, the results emphasized a reduction of the painful syndrome, if present, an improvement of the psychological state and particularly of appetite, also by reason of the consequent reduced intake of analgesic and adjuvant drugs.

KW - MPA

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=0028227623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028227623&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0028227623

VL - 14

SP - 75

EP - 78

JO - Giornale Italiano di Oncologia

JF - Giornale Italiano di Oncologia

SN - 0392-128X

IS - 2

ER -